Biocon Secures Entry for Stelara Biosimilar Yesintek in Nine More Global Markets via Janssen Licence
A fresh licence agreement with Janssen Sciences Ireland lets Biocon commercialise Yesintek, its ustekinumab biosimilar, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, subject to local regulatory approvals.
